AstraZeneca: Alexion presents Phase III HICKORY data for efzimfotase alfa

AstraZeneca's Alexion unit will present Phase III HICKORY results for efzimfotase alfa in hypophosphatasia at the ASBMR meeting in Boston on Oct. 9-12, 2026. Data are positioned to support broader use in adult-onset disease.